Biolyst › AGENAGENUS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 1.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 26 concluded trials, 58% reached completion rather than being terminated or withdrawn.
Track AGEN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AGEN in the tracker
Recent history
Date Event Type Phase
August 18, 2026
8-K filed: Material agreement Corporate
—
August 13, 2026
8-K filed: Leadership change Corporate
—
August 11, 2026
8-K filed: Leadership change Corporate
—
August 6, 2026
Quarterly results filed (8-K) Earnings
—
July 13, 2026
8-K filed: Material agreement, Reg FD disclosure, Other event Corporate
—
July 6, 2026
8-K filed: Material agreement Corporate
—
May 15, 2026
8-K filed: Leadership change Corporate
—
May 11, 2026
Quarterly results filed (8-K) Earnings
—
March 26, 2026
8-K filed: Other event Filing
—
March 16, 2026
Quarterly results filed (8-K) Earnings
—
January 16, 2026
8-K filed: Acquisition completed, Reg FD disclosure Corporate
—
January 14, 2026
8-K filed: Leadership change Corporate
—
January 8, 2026
8-K filed: Material agreement Corporate
—
January 5, 2026
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Trial Milestone
Phase 2
November 10, 2025
Quarterly results filed (8-K) Earnings
—
October 9, 2025
8-K filed: Material agreement Corporate
—
September 23, 2025
8-K filed: Other event Filing
—
August 11, 2025
Quarterly results filed (8-K) Earnings
—
June 4, 2025
8-K filed: Material agreement, Reg FD disclosure Corporate
—
May 12, 2025
Quarterly results filed (8-K) Earnings
—
March 26, 2025
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer Trial Milestone
Phase 2
January 13, 2025
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Trial Milestone
Phase 1
December 23, 2024
Study of AGEN1571 in Participants With Advanced Solid Tumors Trial Milestone
Phase 1
February 22, 2024
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Trial Milestone
Phase 1
July 11, 2023
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors Trial Milestone
Phase 1
July 15, 2022
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) Trial Milestone
Phase 1/Phase 2
June 15, 2022
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer Trial Milestone
Phase 1/Phase 2
March 30, 2022
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Trial Milestone
Phase 1/Phase 2
April 8, 2021
A Study in Subjects With Advanced Solid Tumors Trial Milestone
Phase 1
February 3, 2021
Phase 1a Study to Evaluate Immunogenicity of ASV® Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.